Skip to main content

Table 4 Factors associated with index tumor volume > 0.718 in entire cohort and each risk group

From: Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy

  Entire cohort
  Univariate analyses   Multivariate analyses
  OR 95%CI p-value OR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 3.780 1.520–9.440 0.004 2.860 1.060–7.680 0.038
% positive cores >21.4 vs ≤21.4% 6.640 3.520–12.50 <0.001 5.110 2.660–9.840 <0.001
% dominant side >37.5 vs ≤37.5% 6.140 3.250–11.60 <0.001    
% cancer extent >55.6 vs ≤55.6% 3.240 1.790–5.880 <0.001 2.370 1.250–4.520 0.009
NCCN risk high vs intermediate 1.220 0.717–2.070 0.465    
  Intermediate-risk
  Univariate analyses   Multivariate analyses
  OR 95%CI p-value OR 95%CI p-value
PSAD >0.190 vs ≤0.190 ng/ml/cc 2.330 1.190–4.560 0.014    
% positive cores >21.4 vs ≤21.4% 8.050 3.320–19.50 <0.001 6.760 2.750–16.70 <0.001
% dominant side >36.4 vs ≤36.4% 5.900 2.610–13.40 <0.001    
% cancer extent >57.1 vs ≤57.1% 3.460 1.570–7.650 0.002 2.370 1.010–5.58 0.048
  High-risk
  Univariate analyses   Multivariate analyses
  OR 95%CI p-value OR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 1.950 0.643–5.900 0.239    
% positive cores >35.0 vs ≤35.0% 7.380 1.610–33.90 0.010 7.380 1.610–33.90 0.010
% dominant side >40.0 vs ≤40.0% 3.560 1.390–9.100 0.008    
% cancer extent >55.6 vs ≤55.6% 2.410 0.959–6.050 0.061    
  1. OR Odds ratio, 95%CI 95% confidence interval, % dominant side % positive cores from dominant side, % cancer extent maximum % of cancer extent in each positive core, Bold indicates statistically significant